



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Ligufalimab

|           |                                                                                           |
|-----------|-------------------------------------------------------------------------------------------|
| Cat. No.: | HY-P99706                                                                                 |
| CAS No.:  | 2428381-55-7                                                                              |
| Target:   | Interleukin Related; CD47                                                                 |
| Pathway:  | Immunology/Inflammation                                                                   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------------------------------------------------------------------------------|---------|---------------------------------------------------------------------------|-----------------|------|---------|------------------------------------------------------------------------------------------|
| <b>Description</b> | Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity <sup>[1]</sup> .                                                                                                                                                                                                                                                   |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |
| <b>In Vitro</b>    | Ligufalimab binds to human CD47 antigen with an EC <sub>50</sub> value of 0.078 nM, K <sub>D</sub> value of 0.152 nM <sup>[1]</sup> .<br>Ligufalimab (0-3000 nM) does not induce RBC hemagglutination <sup>[1]</sup> .<br>Ligufalimab (0.1, 1, 10 µg/mL) induces phagocytosis of Raji, Jurkat and Ramos cells in a dose-dependent manner <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |
| <b>In Vivo</b>     | Ligufalimab (0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) inhibits tumor growth in mice <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.                                                                                                                                                                                                                    |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |
|                    | <table border="1"> <tr> <td>Animal Model:</td> <td>SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model</td> </tr> <tr> <td>Administration:</td> <td>I.v.</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg.</td> </tr> </table>       | Animal Model: | SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model) <sup>[1]</sup> | Dosage: | 0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model | Administration: | I.v. | Result: | Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg. |
| Animal Model:      | SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model) <sup>[1]</sup>                                                                                                                                                                                                                                                                                                                                                                            |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |
| Dosage:            | 0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model                                                                                                                                                                                                                                                                                                                                                                                    |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |
| Administration:    | I.v.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |
| Result:            | Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg.                                                                                                                                                                                                                                                                                                                                                                     |               |                                                                                   |         |                                                                           |                 |      |         |                                                                                          |

### REFERENCES

[1]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10(11):e005517.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA